Nifty
Sensex
:
:
11895.45
40356.69
23.35 (0.20%)
70.21 (0.17%)

Pharmaceuticals & Drugs

Rating :
63/99  (View)

BSE: 532523 | NSE: BIOCON

257.25
2.55 (1.00%)
15-Nov-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  255.00
  •  262.00
  •  253.10
  •  254.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1929705
  •  4964.17
  •  341.23
  •  211.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 30,876.00
  • 36.20
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 32,241.80
  • 0.19%
  • 4.84

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 1.49%
  • 12.04%
  • FII
  • DII
  • Others
  • 1.05%
  • 3.96%
  • 20.79%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.82
  • 12.28
  • 12.32

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.45
  • 14.90
  • 7.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 12.70
  • 14.93

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.16
  • 26.88
  • 44.63

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.76
  • 4.55
  • 5.64

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.82
  • 21.07
  • 26.48

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
1,572.20
1,321.00
19.02%
1,465.90
1,123.80
30.44%
1,528.80
1,169.50
30.72%
1,540.80
1,057.90
45.65%
Expenses
1,169.40
981.40
19.16%
1,028.40
886.00
16.07%
1,125.80
936.50
20.21%
1,160.10
836.20
38.73%
EBITDA
402.80
339.60
18.61%
437.50
237.80
83.98%
403.00
233.00
72.96%
380.70
221.70
71.72%
EBIDTM
25.62%
25.71%
29.85%
21.16%
26.36%
19.92%
24.71%
20.96%
Other Income
38.40
54.40
-29.41%
24.10
68.80
-64.97%
28.20
67.50
-58.22%
25.60
33.90
-24.48%
Interest
13.80
18.80
-26.60%
16.60
17.60
-5.68%
15.90
16.90
-5.92%
18.60
14.70
26.53%
Depreciation
131.60
112.20
17.29%
124.20
99.10
25.33%
119.80
95.30
25.71%
116.70
97.40
19.82%
PBT
363.30
451.80
-19.59%
320.80
189.90
68.93%
295.50
188.30
56.93%
276.80
143.50
92.89%
Tax
100.10
73.20
36.75%
85.20
52.10
63.53%
40.90
40.70
0.49%
46.10
36.10
27.70%
PAT
263.20
378.60
-30.48%
235.60
137.80
70.97%
254.60
147.60
72.49%
230.70
107.40
114.80%
PATM
16.74%
28.66%
16.07%
12.26%
16.65%
12.62%
14.97%
10.15%
EPS
0.00
2.96
-100.00%
1.72
1.00
72.00%
1.78
1.09
63.30%
1.81
0.77
135.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
6,107.70
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
Net Sales Growth
30.72%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
 
Cost Of Goods Sold
1,918.40
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
Gross Profit
4,189.30
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
GP Margin
68.59%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
Total Expenditure
4,483.70
4,120.70
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
Power & Fuel Cost
-
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
% Of Sales
-
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
Employee Cost
-
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
% Of Sales
-
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
Manufacturing Exp.
-
451.30
335.70
391.50
320.90
81.20
62.90
95.20
113.20
81.60
68.63
% Of Sales
-
8.18%
8.14%
10.06%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
General & Admin Exp.
-
53.00
56.80
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
% Of Sales
-
0.96%
1.38%
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
Selling & Distn. Exp.
-
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
% Of Sales
-
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
Miscellaneous Exp.
-
37.20
47.40
41.00
30.10
72.70
61.80
52.90
256.70
940.80
56.49
% Of Sales
-
0.67%
1.15%
1.05%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
EBITDA
1,624.00
1,393.70
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
EBITDA Margin
26.59%
25.27%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
Other Income
116.30
144.40
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
Interest
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
Depreciation
492.30
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
PBT
1,256.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
Tax
272.30
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
Tax Rate
21.67%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
PAT
984.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
PAT before Minority Interest
868.90
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
Minority Interest
-115.20
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
PAT Margin
16.11%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
PAT Growth
27.57%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
 
Unadjusted EPS
5.31
15.30
6.31
10.39
28.04
24.87
21.09
25.99
17.27
18.79
15.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
Share Capital
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
5,720.80
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
Non-Current Liabilities
2,123.20
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
Secured Loans
1,539.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
Unsecured Loans
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
Long Term Provisions
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
Current Liabilities
3,037.60
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
Trade Payables
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
Other Current Liabilities
1,373.80
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
Short Term Borrowings
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
Short Term Provisions
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
Total Liabilities
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
Net Block
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
Gross Block
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
Accumulated Depreciation
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
Non Current Assets
7,044.90
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
Capital Work in Progress
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
Non Current Investment
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
Long Term Loans & Adv.
401.50
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
0.00
Other Non Current Assets
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
0.00
Current Assets
4,822.80
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
Current Investments
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
Inventories
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
Sundry Debtors
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
Cash & Bank
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
Other Current Assets
612.90
373.30
395.80
73.60
171.60
157.60
136.90
114.30
56.70
136.10
Short Term Loans & Adv.
46.40
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
120.28
Net Current Assets
1,785.20
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
Total Assets
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,154.60
662.10
640.00
526.40
210.70
560.70
471.20
564.10
798.50
443.81
PBT
1,214.90
610.00
849.70
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
Adjustment
260.30
355.70
204.40
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
Changes in Working Capital
-29.10
-106.50
-211.10
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
Cash after chg. in Working capital
1,446.10
859.20
843.00
773.20
344.10
709.40
565.20
638.00
879.80
476.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-291.50
-197.10
-203.00
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-713.80
-684.00
-498.50
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
Net Fixed Assets
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
Net Investments
184.70
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
Others
-617.90
-195.40
-203.30
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
Cash from Financing Activity
-241.70
-239.70
-177.50
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
Net Cash Inflow / Outflow
199.10
-261.60
-36.00
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
Opening Cash & Equivalents
449.00
710.20
757.50
462.60
557.00
474.00
369.00
359.00
139.90
11.81
Closing Cash & Equivalent
659.30
449.00
710.20
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
50.17
42.59
39.74
33.61
26.93
24.21
21.59
18.16
16.25
14.13
ROA
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
ROE
18.00%
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
ROCE
16.10%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
Fixed Asset Turnover
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
Receivable days
77.96
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
Inventory Days
58.05
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
Payable days
86.75
87.98
78.68
68.27
58.15
55.73
65.24
70.25
70.62
41.52
Cash Conversion Cycle
49.26
58.07
50.48
65.60
70.42
62.29
62.99
81.79
100.29
71.30
Total Debt/Equity
0.40
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
Interest Cover
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81

News Update


  • Biocon gets EIR from USFDA for Biologics Drug Product facility in Bengaluru
    5th Nov 2019, 09:48 AM

    This reaffirms Biocon Biologics' global scale manufacturing capability for high quality, affordable biosimilars for the US market

    Read More
  • Biocon features in Science Careers’ top 20 global pharma & biotech employers list 2019
    29th Oct 2019, 10:08 AM

    Ranked at No. 6 among global pharma and biotech companies in 2019, the company has moved up from No. 7 in 2018 and No. 9 in 2017

    Read More
  • Biocon reports 39% fall in Q2 consolidated net profit
    24th Oct 2019, 12:45 PM

    Total consolidated income of the company increased by 17.10% at Rs 1610.60 crore for Q2FY20

    Read More
  • Biocon - Quarterly Results
    23rd Oct 2019, 18:21 PM

    Read More
  • Biocon’s arm, Just - Evotec Biologics sign licensing deal for biosimilar asset
    11th Oct 2019, 09:42 AM

    Through this in-licensing deal, Biocon Biologics has expanded its current therapeutic basket of biosimilars going beyond diabetes, oncology and immunology

    Read More
  • Biocon, Mylan NV launch Semglee in Australia
    3rd Oct 2019, 09:04 AM

    Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar levels of those with diabetes

    Read More
  • Biocon’s arm acquires R&D capital assets from Pfizer Healthcare India
    24th Sep 2019, 09:11 AM

    The new facility provides Biocon Biologics a significant time advantage in comparison to setting up a Greenfield R&D project

    Read More
  • USFDA completes inspection at Biocon’s two facilities in Bengaluru
    21st Sep 2019, 10:33 AM

    The company has received a Form 483 with four observations for the new DS facility

    Read More
  • Biocon signs agreement with China Medical System Holdings’ arm
    13th Sep 2019, 09:56 AM

    The company has signed License and Supply Agreement for three Generic Formulation products in Greater China

    Read More
  • Biocon’s arm receives certificate of GMP compliance
    22nd Aug 2019, 09:01 AM

    This approval expands the company’s capacities multi-fold with the new large scale devices facility

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.